Seropositivity of selected chronic infections and different measures of obesity

PLoS One. 2020 Apr 22;15(4):e0231974. doi: 10.1371/journal.pone.0231974. eCollection 2020.

Abstract

The impact of sex-specific body fat distribution on the susceptibility to five chronic infections, helicobacter pylori and human herpesviruses 3 to 6 (i.e. varicella-zoster, Epstein-Barr, cytomegalo- and human herpesvirus 6), has not previously been examined. In the present study, seropositivity was determined via multiplex serology in serum samples of study participants collected in 2006/08 and 2013/14 during the follow-up examinations F4 (n = 3080) and FF4 (n = 2279) of the German population-based baseline KORA S4 survey. We quantified the severity of overall and abdominal obesity by body mass index, body adiposity index, waist circumference, waist-to-hip ratio, and waist-to-height ratio. Using sex-specific logistic spline-models, cross-sectional and longitudinal associations between obesity measures and seropositivity of the previously mentioned infections were investigated. Overall and abdominal fat content were significantly associated with seropositivity of varicella-zoster virus in both cross-sectional and longitudinal analyses among women. In addition, a non-significant inverse relationship with Epstein-Barr virus seroprevalence in both sexes and a trend towards a positive association with human herpesvirus 6 seropositivity in women were observed. Therefore, in women total body fat may be associated with VZV-seropositivity and may influence the reactivation of the varicella-zoster virus, independent of adipose tissue distribution.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Chronic Disease
  • Female
  • Humans
  • Infections / blood*
  • Infections / complications*
  • Male
  • Middle Aged
  • Obesity / complications*
  • Seroepidemiologic Studies
  • Surveys and Questionnaires

Grants and funding

This work was supported by iMed – the Helmholtz Association’s Cross Programme Initiative on Personalized Medicine and the Helmholtz Association’s Portfolio Topic “Metabolic Dysfunction and Chronic Diseases”. The KORA study was initiated and financed by the Helmholtz Zentrum München – German Research Centre for Environmental Health, which is funded by the German Federal Ministry of Education and Research (BMBF) and by the State of Bavaria. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.